EBV+ diffuse large B-cell lymphoma associated with chronic ...

LETTER TO BLOOD| MAY 28, 2020

EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant–related lymphomas

Lénaïg Mescam, Vincent Camus, Jean-Marc Schiano, José Adélaïde, Jean-Michel Picquenot, Arnaud Guille, Marie Bannier, Philippe Ruminy, Pierre-Julien Viailly, Fabrice Jardin, Reda Bouabdallah, Isabelle Brenot-Rossi, Elodie Bohers, Cyrielle Robe, Camille Laurent, Daniel Birnbaum, Andrew Wotherspoon, Philippe Gaulard, Luc Xerri

Blood (2020) 135 (22): 2004–2009.

https://doi.org/10.1182/blood.2019003408

Subjects:

Clinical Trials and Observations, Lymphoid Neoplasia

Topics:

breast implants, chronic inflammation, diffuse large b-cell lymphoma, herpesvirus 4, human, lymphoma, ki-1+ anaplastic large cell lymphoma, t-cell lymphoma

TO THE EDITOR:

Breast implant–associated anaplastic large cell lymphoma (BI-ALCL) has emerged as a new provisional entity in the revised 2016 World Health Organization classification of lymphoid malignancies.1  BI-ALCL is a rare T-cell lymphoma arising adjacent to breast implants and composed of large atypical CD30+ cells frequently confined to the peri-implant seroma fluid and adjacent capsule, more rarely forming a solid infiltrating mass.2,3  So far, only exceptional cases of lymphomas other than BI-ALCL have been reported to occur in the vicinity of breast implants, including miscellaneous B-cell lymphomas.4-7  It remains so far unclear whether these cases are coincidental or could be related to breast implants.

We report 3 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphomas (DLBCLs) occurring in contact with breast implants. These cases were also characterized by various degrees of invasion of the...

REFERENCES

1.WHO Classification of tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. Lyon: International Agency for Research on Cancer; 2017.

2.Laurent C, Delas A, Gaulard P, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol. 2016;27(2):306-314.

3.Laurent C, Haioun C, Brousset P, Gaulard P. New insights into breast implant-associated anaplastic large cell lymphoma. Curr Opin Oncol. 2018;30(5):292-300.

4.Said JW, Tasaka T, Takeuchi S, et al. Primary effusion lymphoma in women: report of two cases of Kaposi’s sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood. 1996;88(8):3124-3128.

5.Smith BK, Gray SS. Large B-cell lymphoma occurring in a breast implant capsule. Plast Reconstr Surg. 2014;134(4):670e-671e.

6.Messer A, Jenkinson H, Wang W, Duvic M. New B-cell lymphomas in the setting of a previous rare breast implant-associated B-cell lymphoma. Plast Reconstr Surg Glob Open. 2016;4(11):e1148.

7.Chen V, Hoang D, Clancy S. Breast implant-associated bilateral B-cell lymphoma. Aesthet Surg J. 2020;40(2):NP52-NP58.

8.Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24(9):2236-2244.

9.Yhim H-Y, Kim JS, Kang HJ, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer. 2012;131(1):235-243.

10.Rajeev A, Ralte A, Choudhry N, Jabbar F, Banaszkiewicz P. Diffuse B cell non-Hodgkin’s lymphoma presenting atypically as periprosthetic joint infection in a total hip replacement. Case Rep Orthop. 2017;2017:7195016. 10.1155/2017/7195016

11.Sanchez-Gonzalez B, Garcia M, Montserrat F, et al. Diffuse large B-cell lymphoma associated with chronic inflammation in metallic implant. J Clin Oncol. 2013;31(10):e148-e151.

12.Narimatsu H, Ota Y, Kami M, et al. Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol. 2007;18(1):122-128.

13.Loong F, Chan ACL, Ho BCS, et al. Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios. Mod Pathol. 2010;23(4):493-501.

14.Boroumand N, Ly TL, Sonstein J, Medeiros LJ. Microscopic diffuse large B-cell lymphoma (DLBCL) occurring in pseudocysts: do these tumors belong to the category of DLBCL associated with chronic inflammation? Am J Surg Pathol. 2012;36(7):1074-1080.

15.Yan J, Luo D, Zhang F, et al. Diffuse large B cell lymphoma associated with chronic inflammation arising within atrial myxoma: aggressive histological features but indolent clinical behaviour. Histopathology. 2017;71(6):951-959.

16.Kameda K, Shono T, Takagishi S, et al. Epstein-Barr virus-positive diffuse large B-cell primary central nervous system lymphoma associated with organized chronic subdural hematoma: a case report and review of the literature. Pathol Int. 2015;65(3):138-143.

17.Boyer DF, McKelvie PA, de Leval L, et al. Fibrin-associated EBV-positive large B-cell lymphoma: an indolent neoplasm with features distinct from diffuse large B-cell lymphoma associated with chronic inflammation. Am J Surg Pathol. 2017;41(3):299-312.

18.Petitjean B, Jardin F, Joly B, et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am J Surg Pathol. 2002;26(6):724-732.

19.Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011;117(18):4726-4735.

20.Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014;99(7):e105-e107.

21.Zhou XA, Louissaint A Jr., Wenzel A, et al. Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2018;138(11):2365-2376.

22.Laurent C, Nicolae A, Laurent C, et al. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. Blood. 2020;135(5):360-370.

23.Kanno H, Naka N, Yasunaga Y, et al. Production of the immunosuppressive cytokine interleukin-10 by Epstein-Barr-virus-expressing pyothorax-associated lymphoma: possible role in the development of overt lymphoma in immunocompetent hosts. Am J Pathol. 1997;150(1):349-357.

24.Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol. 1990;64(6):3033-3041.

25.Calobrace MB, Schwartz MR, Zeidler KR, Pittman TA, Cohen R, Stevens WG. Long-term safety of textured and smooth breast implants. Aesthet Surg J. 2017;38(1):38-48.

© 2020 by The American Society of Hematology

This program is developed by Focus Insight with the permission of American Society of Hematology, Inc. The content are excerpted from the journal Blood. Copyright © 2019 The American Society of Hematology. All rights reserved. 「American Society of Hematology」, 「ASH」 and the ASH Logo are registered trademarks of the American Society of Hematology.